The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2016:
- 32 negotiations are currently underway with 2 files added since the last update of June 30, 2016:
- Avastin (bevacizumab): used to treat genitourinary platinum-resistant ovarian cancer
- Opdivo (nivolumab): used to treat advanced or metastatic non-small cell lung cancer
- 112 joint negotiations have been completed with 3 files completed since the last update of June 30, 2016:
- Breo Ellipta (fluticasone furoate/vilanterol): used for the treatment of asthma
- Iclusig (ponatinib): used to treat Chronic Myeloid Leukemia (CML)/Acute Lymphoblastic Leukemia
- Simponi (golimumab) SC: used to treat ulcerative colitis
- 38 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update of June 30, 2016.
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of June 30, 2016.
For more information, please consult the pCPA’s website.